Cetrorelix

Overview

Cetrorelix, marketed as Cetrotide, is a synthetic peptide that acts as a gonadotropin-releasing hormone antagonist. It is FDA-approved for use during controlled ovarian stimulation in assisted reproduction, specifically to prevent a premature surge of luteinizing hormone, or LH, during in vitro fertilization, or IVF, treatment cycles.

During fertility treatment, the ovaries are stimulated to develop multiple follicles. A premature LH surge could trigger eggs to be released too early, before they can be retrieved, compromising the cycle. Cetrorelix is given to hold back that surge until the optimal time for egg retrieval is reached, helping the treatment team control the timing precisely.

A key practical advantage of cetrorelix is that, as a GnRH antagonist, it suppresses hormones immediately and does not cause the initial flare seen with GnRH agonists. This allows it to be introduced at a specific point in the stimulation cycle and removed when no longer needed, supporting shorter and more flexible IVF protocols.

How it works

Gonadotropin-releasing hormone normally binds receptors in the pituitary gland to stimulate the release of luteinizing hormone and follicle-stimulating hormone. Cetrorelix is a GnRH antagonist, meaning it competitively blocks these receptors rather than activating them. By occupying the receptors, it prevents the body's own GnRH from triggering hormone release.

This produces an immediate and dose-dependent suppression of luteinizing hormone and, to a lesser extent, follicle-stimulating hormone. The effect is essentially a rapid switch-off, in contrast to GnRH agonists, which first overstimulate the receptors and cause a temporary surge before suppression develops. The absence of this flare is a defining feature of antagonists.

In the context of IVF, this means cetrorelix can be started once follicles have grown to a certain stage, suppressing a premature LH surge without delaying the early phase of stimulation. Because the blockade is competitive and reversible, pituitary responsiveness returns after the drug is stopped, allowing the treatment team to trigger final egg maturation at the chosen moment.

Clinical evidence

Cetrorelix is supported by clinical studies in women undergoing controlled ovarian stimulation for assisted reproduction. These trials evaluated its ability to prevent premature LH surges during IVF cycles and established its role within antagonist protocols, which have become a widely used approach in fertility care.

Comparative research in reproductive medicine has examined GnRH antagonist protocols against older agonist-based approaches, looking at outcomes such as the prevention of premature ovulation, the number of eggs retrieved, treatment duration, and the convenience of shorter regimens. Antagonist protocols are often valued for their flexibility and for considerations related to the risk of ovarian hyperstimulation, though specific outcomes depend on individual patient factors.

The evidence positions cetrorelix as an effective tool for cycle control rather than a treatment that independently determines success. IVF outcomes depend on many variables, including age, ovarian reserve, and the overall protocol. Honest framing recognizes that cetrorelix performs a specific, well-defined job, preventing a premature LH surge, within a larger and individualized treatment plan.

Dosing & side effects

Cetrorelix is given as a subcutaneous injection during a defined window of the ovarian stimulation cycle, typically self-administered by the patient after instruction from the fertility team. This guide does not provide doses or timing; the specific regimen is determined by the treating clinician based on the protocol and the individual's response to stimulation, and is detailed in the product instructions.

Common side effects include reactions at the injection site, such as redness, itching, or swelling. Some people experience mild, transient symptoms related to the treatment cycle. As with other reproductive medications, allergic and hypersensitivity reactions are possible, and any signs of a serious reaction should receive immediate medical attention.

Cetrorelix is used as part of a closely monitored treatment cycle, with the fertility team tracking follicle development through ultrasound and hormone measurements to time the medication and the final trigger appropriately. It is not intended for use outside of supervised assisted reproduction, and it should not be used during pregnancy. Patients are encouraged to report any concerning symptoms to their clinic promptly.

Legal status

Cetrorelix is an approved prescription medication used in assisted reproduction, available only through a licensed prescriber, typically within a fertility clinic. It is not available over the counter and is not a controlled substance. Its use is generally confined to supervised IVF and related treatment cycles.

Regulatory labeling defines its specific indication in controlled ovarian stimulation, and clinical use follows established fertility protocols. Because timing is critical, administration is closely coordinated with monitoring performed by the treatment team, even when the injections themselves are self-administered.

Brand availability and approved uses can vary by country and may change over time, and other GnRH antagonists may be available in some markets. Patients undergoing fertility treatment should rely on their clinic, prescriber, and pharmacist for current information about the appropriate product, timing, and administration within their individual treatment plan.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Lee TH, Lin YH, Seow KM, et al. Effectiveness of cetrorelix for prevention of premature LH surge during controlled ovarian stimulation: a randomized trial. Fertil Steril. 2008. Peer-reviewed study
2. Lin YH, Seow KM, Chen HJ, et al. Effect of cetrorelix dose on premature LH surge during ovarian stimulation. Reprod Biomed Online. 2008. Peer-reviewed study
3. Finas D, Hornung D, Diedrich K, et al. Cetrorelix in the treatment of female infertility and endometriosis. Expert Opin Pharmacother. 2006. Peer-reviewed study
4. Tur-Kaspa I, Ezcurra D. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology. Expert Opin Drug Metab Toxicol. 2009. Peer-reviewed study
5. Reissmann T, Schally AV, Bouchard P, et al. The LHRH antagonist cetrorelix: a review. Hum Reprod Update. 2000. Peer-reviewed study
6. Kanda A, Nobukiyo A, Sotomaru Y. Effect of Cetrorelix administration on ovarian stimulation in aged mice. Exp Anim. 2021. Peer-reviewed study